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ABSTRACT
Runx1 is a well characterized transcription factor essential for hematopoietic 
differentiation and Runx1 mutations are the cause of leukemias. Runx1 is highly 
expressed in normal epithelium of most glands and recently has been associated 
with solid tumors. Notably, the function of Runx1 in the mammary gland and how 
it is involved in initiation and progression of breast cancer is still unclear. Here we 
demonstrate the consequences of Runx1 loss in normal mammary epithelial and 
breast cancer cells. We first observed that Runx1 is decreased in tumorigenic and 
metastatic breast cancer cells. We also observed loss of Runx1 expression upon 
induction of epithelial-mesenchymal transition (EMT) in MCF10A (normal-like) cells. 
Furthermore depletion of Runx1 in MCF10A cells resulted in striking changes in cell 
shape, leading to mesenchymal cell morphology. The epithelial phenotype could be 
restored in breast cancer cells by re-expressing Runx1. Analyses of breast tumors and 
patient data revealed that low Runx1 expression is associated with poor prognosis 
and decreased survival. We addressed mechanisms for the function of Runx1 in 
maintaining the epithelial phenotype and find Runx1 directly regulates E-cadherin; 
and serves as a downstream transcription factor mediating TGFβ signaling. We also 
observed through global gene expression profiling of growth factor depleted cells that 
induction of EMT and loss of Runx1 is associated with activation of TGFβ and WNT 
pathways. Thus these findings have identified a novel function for Runx1 in sustaining 
normal epithelial morphology and preventing EMT and suggest Runx1 levels could be 
a prognostic indicator of tumor progression.
INTRODUCTION
Evidence is rapidly accruing for the oncogenic 
and tumor suppressor functions of the Runx family of 
transcription factors, Runx1, Runx2 and Runx3, which 
are essential for normal lineage specific development 
[1, 2]. In late stage cancer, including breast, prostate and 
thyroid, abnormal expression of Runx2 drives metastasis 
to bone [3–5]. Inhibition of Runx2 in metastatic breast 
and prostate cancer cells drastically reduces tumor 
growth and metastasis in vivo [3, 6], revealing Runx2 
function as an oncogene. It has been well documented 
that translocations of Runx1, the essential hematopoiesis 
factor, with ETO, TEL (ETV6) [7] or other genes cause a 
wide range of leukemias [8]. However, little is known of 
Runx1 oncogenic or tumor suppressor activities in solid 
tumors. An early microarray profiling study comparing 
adenocarcinoma metastasis with primary adenocarcinoma 
tumors identified Runx1 as one of 17 genes signature 
that associate with metastasis [9]. Recent genetic studies 
have identified loss-of-function somatic mutations or 
deletion of Runx1 in breast cancer patients [10, 11]. 
These data are consistent with evidence that Runx1 is 
reduced in metastasis-prone solid tumors [9]. There is a 
requirement for understanding Runx1-mediated regulatory 
mechanism(s) in breast cancer.
Breast cancer remains the leading cause of cancer 
related death in women worldwide [12]. Among the 
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different subtypes of breast cancer, both the basal-like 
and Her2-enriched subtypes are the most clinically 
challenging; they have the worst survival rates and 
are often associated with metastasis [13]. It has been 
speculated that this aggressive phenotype of basal like 
breast cancer is linked with the Epithelial to Mesenchymal 
Transition (EMT), which is a key biological process in 
cancer progression and is involved in the conversion 
of early stage tumors into invasive malignancies [14]. 
Oncogenic EMT occurs when primary tumor cells 
undergo a switch from an epithelial phenotype, which 
lacks motility and exhibits extensive cell-to-cell contact, 
to a mesenchymal phenotype having high cellular motility, 
lower cellular interactions, and a non-polarized cell 
organization [15]. Several studies, using breast cancer 
cell lines and clinical samples, have demonstrated that 
increased expression of mesenchymal markers including 
Vimentin, Fibronectin and N-cadherin, as well as reduced 
expression of epithelial markers including E-cadherin 
are observed in basal subtype breast cancer [8–11]. 
The specific mechanisms that preserve the structural 
and functional properties of the epithelial cells of the 
glandular tissues and protect normal epithelial cells from 
transitioning to malignancy in basal like breast cancer 
are compelling unresolved questions. We therefore have 
focused our studies on the functional activities of Runx1 
in basal subtype breast cancer cells.
In this study, we hypothesize that Runx1 maintains 
the normal epithelial phenotype and that loss of Runx1 
promotes EMT. Our results demonstrate that depletion of 
Runx1 in mammary epithelial cells disrupts/alters cellular 
morphology and suppress E-cadherin expression. We find 
that Runx1 level decreases during both TGFβ-induced 
and growth factor-starvation induced EMT, supporting a 
crucial role for Runx1 in preventing EMT. Furthermore 
our analysis of breast tumors and survival data supports 
the above finding that loss of Runx1 promotes tumor 
progression. Thus, these studies demonstrate that Runx1 
functions to preserve epithelial phenotype in mammary 
epithelial cells and reveal that Runx1 has tumor suppressor 
potential in breast cancer.
RESULTS
Runx1 expression is decreased in breast cancer
Runx1 involvement in breast cancer was first tested 
using a panel of normal and breast cancer cell lines 
representing different breast cancer subtypes (Figure 1). 
The selected cell lines included non-metastatic luminal-
like MCF7 and T47D breast cancer cells and basal-like 
breast cancer MDA-MB-231 cells. Compared to the high 
level of Runx1 in normal-like basal MCF10A control cells, 
Runx1 mRNA (Figure 1A) and protein (Figure 1B) were 
significantly decreased in all breast cancer cell lines tested, 
but less so in the triple negative MDA-MB-231 cells.
We next evaluated Runx1 mRNA and protein 
expression in the MCF10 progression series of MCF10A 
normal-like mammary epithelial cells, tumorigenic 
MCF10AT1 and MCF10CA1a cells [16]. Runx1 mRNA 
(Figure 1C) and protein (Figure 1D) expression were 
strikingly decreased in both MCF10AT1 and MCF10CA1a 
cells compared with MCF10A cells. In both early and 
aggressive cancer cell types, loss of Runx1 expression 
paralleled decreases of the epithelial marker E-cadherin, 
while the mesenchymal marker Vimentin was highly 
expressed only in the MCF10CA1a cells. These changes 
in EMT markers are consistent with the mesenchymal 
phenotype of the two cancer cell lines. Thus decreased 
Runx1 with tumor progression correlates with EMT. 
Together our findings indicate an important role for Runx1 
in normal breast epithelial cells and provide evidence for 
the emerging concept that Runx1 may function as a tumor 
suppressor [17].
TGFβ induced EMT decreases Runx1 expression 
in MCF10A cells
The above results show that Runx1 levels are 
decreased in breast cancer cells and that decreased Runx1 
is accompanied with EMT in the MCF10 series. To 
mechanistically address if decreased Runx1 and EMT are 
coupled in breast cancer, we used a well-known method 
to induce EMT in mammary cells, by adding TGFβ to 
MCF10A cells [18]. TGFB1-Smad signaling is the most 
frequently described inducer of EMT, and Runx1 is known 
to be a downstream target of TGFβ signaling. Furthermore 
it is well documented that Runx1 forms an interaction 
complex with SMADs [19], thereby regulating genes 
responsive to TGFβ. Taken together, we hypothesized that 
Runx1 expression would be repressed upon treating with 
TGFβ.
MCF10A cells were incubated with 10 ng/ml 
TGFβ1 for 6 days, and we observed that the original 
cobblestone-like epithelial morphology with tight cell-
cell contact was lost, and cells gained an elongated 
fibroblast-like morphology (Figure 2A). When the levels 
of epithelial and mesenchymal markers were examined 
by western blotting and immunofluorescence microscopy, 
the TGFβ1 treated cells exhibited a 50% down-regulation 
of the epithelial marker E-cadherin, while expression of 
the mesenchymal markers Vimentin and N-cadherin was 
induced (Figure 2B). Significantly, in this TGFβ induced 
EMT model, we observed the down regulation of Runx1 
in both protein and mRNA levels (Figure 2B). Although 
the immunofluorescence results showed that not all 
cells acquired the mesenchymal phenotype (Figure 2C), 
indicating that only a subset of the cells underwent EMT, 
we still find that Runx1 is decreased during EMT. As 
further evidence that loss of Runx1 occurs concomitantly 
with EMT, co-immunofluorescence reveals that the subset 
of cells undergoing EMT (Vimentin positive cells), had 
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Figure 1: Decreased Runx1 expression is related to breast cancer progression in cell models. A. Runx1 RNA expression by 
RT-qPCR for a panel of breast cancer cell lines compared to MCF10A cells show that Runx1 protein is decreased in breast cancer cells. B. 
Western blot of cell lysate for the same panel of cell lines shown in A. C. Runx1 RNA expression by RT-qPCR of normal mammary-like 
MCF10A cells, MCF10A-derived tumorigenic cell line MCF10AT1, and metastatic MCF10CA1a cells shows Runx1 is decreased in the 
cancer cells. D. Western blot comparison in the MCF10 series.
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lower or no Runx1 expression (Figure 2D). These results 
support the idea that Runx1 may function as a suppressor 
for the EMT.
Runx1 rescues the TGFβ-induced EMT 
phenotype
To further prove a functional role for Runx1 in 
preventing EMT and maintaining the epithelial phenotype, 
we examined whether overexpressing Runx1 could reverse 
the EMT phenotype after TGFβ induction.
A plasmid containing HA-tagged Runx1 was 
transfected into TGFβ treated MCF10A cells. We observed 
that the cells with Runx1 overexpression changed their 
morphology from mesenchymal-like back to epithelial-
like (Figure 3A). Overexpressing Runx1 in these cells also 
increased E-cadherin and repressed Vimentin expression, 
suggesting that cells re-acquired an epithelial phenotype 
and that the TGFβ induced EMT was blocked (Figure 3B). 
This result demonstrated that the repression of Runx1 is a 
necessary step during TGFβ induced EMT.
Decreased expression of Runx1 during TGFβ 
independent EMT in MCF10A cells
We considered the possibility that Runx1 may 
function in a TGFβ independent manner to repress EMT. 
We used a cell model that is independent of exogenous 
TGFβ. It has been previously shown that withdrawal 
from MCF10A medium of specific factors required 
for optimal cell growth (insulin, EGF, Hydrocortisone 
and Cholera Toxin), changed cell morphology from 
cobblestone to spindle like [20]. Here we demonstrate 
that this morphological change (Figure 4A) resembles an 
EMT process. Western blotting and qRT-PCR results show 
that the epithelial marker E-cadherin was down regulated, 
while mesenchymal markers N-cadherin and Vimentin 
were upregulated (Figure 4B and 4C). Importantly Runx1 
protein is not detected in growth factor depleted cells by 
western blot and immunofluorescence microscopy (Figure 
4B and 4D, top panel). Compared with TGFβ induced 
EMT (Figure 2C), in this TGFB independent model, 
all cells acquired the mesenchymal phenotype and lost 
Figure 2: Runx1 decreases during TGFβ-induced EMT. MCF10A cells treated with 10 ng/ml TGFβ for 6 days. A. MCF10A 
cells treated with TGFβ show morphological changes toward an EMT-like state. B. Western blot analyses show changes in EMT markers 
and Runx1 expression during EMT. Left lower panel: RT-qPCR of RNA from MCF10A cells shows decreased Runx1 expression in TGFβ 
treated cells. Student’s t test * p value <0.05 for TGFβ-treated cells compared to control cells. Where error bars are shown these represent 
the standard error of the mean (SEM) from three independent experiments. C. Immunostaining shows increased Vimentin and N-cadherin 
expression in the cytoskeleton during TGFβ-induced EMT. D. Immunostaining shows the cells with Vimentin (Green) expression have less 
or no Runx1 (Red) expression.
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epithelial mark and Runx1 expression (Figure 4D). These 
results reveal that modifying growth medium is a more 
powerful method for inducing EMT in MCF10A cells. 
Based on the loss of Runx1 during both TGFβ-dependent 
and independent EMT, we conclude that Runx1 is a key 
factor in repressing the EMT and maintaining epithelial 
morphology in normal-like mammary epithelial cells.
Gene expression profiling of growth factor-
depleted MCF10A cells reveals the spectrum of 
EMT markers
To further understand the mechanisms of growth 
factor depletion induced EMT, we carried out unbiased 
genome-wide expression profiling by RNA-Seq, 
comparing cells grown in normal and growth factor 
depleted conditions. Among the 1880 differentially 
expressed mRNAs that have a 2-fold cut off, 457 genes 
were up- and 1423 were down-regulated. Gene ontology 
analysis identified functional categories and associated 
pathways (Figure 5). Among the top 5 canonical pathways 
that were affected, regulation of the EMT pathway was 
the most significant with 20 genes altered in the network 
(Figure 5A and 5C). This observation further confirmed 
that this novel method of removing growth factors in 
MCF10A induces EMT. Other relevant pathways include 
cancer metastasis signaling and integrin-like kinase (ILK) 
signaling (Figure 5A). Together these most significant 
signaling pathways are indicative of the MCF10A cells 
acquiring a more cancer related phenotype.
In addition to pathway analysis, we selected 58 
epithelial and mesenchymal genes by using two database 
sources (described in Materials and Methods) and 
examined the expression patterns based on relative reads 
from our RNA-Seq profiling. The heat map constructed 
from these data (Figure 5B) compares expression of EMT 
genes under two different growth conditions—normal 
and growth factor-depleted. Well-established epithelial 
genes such as DSP, Claudins and KRT family [21] were 
down regulated. We observed consistent up-regulation of 
common mesenchymal genes (CDH2, FN1 and VIM) as 
well as genes related to signaling pathways such as BMP/
TGFB and WNT when growth factors were removed. We 
also noted that both TGFβ2 and Runx2 are among up-
regulated genes (Figure 5B). Moreover, we found that 
expression of 43 genes in the Runx2 interaction network 
were altered (Figure 5C), consistent with up-regulation 
of Runx2 protein level upon growth factor depletion 
Figure 3: Runx1 reverses TGFβ induced EMT. A. Images of MCF10A cells treated with TGFβ show morphological changes 
toward an EMT-like state. Overexpressing Runx1 in TGFβ treated cells rescued cell morphology to an epithelial-like state. B. RT-qPCR of 
RNA from MCF10A cells show changes in gene expression by overexpressing Runx1 in TGFβ-treated cells, which activates E-cadherin 
and represses Vimentin expression. Student’s t test * p value <0.05 for HA-Runx1 overexpression in MFC10A cells compared to EV control 
cells. Error bars represent the standard error of the mean (SEM) from three independent experiments.
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Figure 4: Decreased Runx1 during TGFβ-independent EMT. A. Images of MCF10A cells grown in medium without growth 
factors (Insulin, EGF, Hydrocortisone and Cholera toxin) for 7 days show morphological changes from cobblestone to spindle-like. B. 
Western blot analyses of cell lysates from MCF10A cells treated with or without growth factors show changes in EMT markers and Runx1 
expression during EMT. C. RNA expression of the EMT markers E-cadherin, N-cadherin and Fibronectin was quantified using RT-qPCR in 
MCF10A cells in the presence or absence of growth factors. Student’s t test * p value <0.05, ** p value <0.01 for growth factors depleted 
MCF10A cells compared to cells with growth factors. Error bars represent the standard error of the mean (SEM) from three independent 
experiments. D. Immunostaining of E-cadherin, Vimentin, N-Cadherin and Runx1 reveals changes in organization of cell–cell adhesion, 
cytoskeleton and decreased Runx1.
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Figure 5: RNA-Seq reveals MCF10A cells undergo EMT upon growth factor removal. A. Top canonical pathways with the 
most significant p values identified by using Ingenuity Pathway Analysis (QIAGEN, Hilden, Germany). B. Relative expression heat map 
of 58 EMT related genes confirming MCF10A cells undergo EMT. C. Differentially expressed genes (2-fold cut off) in the EMT regulation 
pathway (p val 1.66E-06), Runx1 interaction network (p val 2.56E-02) and Runx2 interaction network (p val 3.73E-09). D. Model of 
Runx1 function in growth factor depletion induced EMT. Illustration shows the consequences of up and down regulated genes when Runx1 
is decreased upon growth factor depletion. The listed genes and pathways are promoting EMT by loss of Runx1 function. Blue indicates 
down regulated genes. Red indicates up regulated genes or pathways. Ingenuity Pathway Analysis (QIAGEN) was used in panel A, C and 
D; GENE-E (Broad Institute, Cambridge, MA, USA) was used in panel B.
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(Supplementary Figure 1) and its role in promoting 
invasion and metastasis to bone [5].
To study how loss of Runx1 is involved in this 
EMT process, we also examined the Runx1 interaction 
network and found that 20 genes (Figure 5C) were altered 
upon growth factor depletion. Further pathway analysis 
with the 1880 differentially expressed genes revealed 
that decreased Runx1 and the altered Runx1 interaction 
network are associated with activation of TGFβ and WNT 
pathways (Figure 5D), which are known to relate to Runx1 
function [22]. The stimulated TGFβ and WNT pathways 
further activate the downstream well-studied EMT-
inducing transcription factors Snail and Twist (Figure 
5D) [21]. These studies provide evidence that depletion 
of Runx1 contributes to initiation of EMT in the normal-
like MCF10A mammary epithelial cells. These results 
also indicate that Runx2 plays an important role during 
growth factor-starvation induced EMT and elucidate 
mechanisms by which Runx1 and Runx2 are involved 
in EMT. Together, these RNA-Seq data confirm that the 
growth factor-starvation method is a unique cell treatment 
to induce EMT in MCF10A cells without exogenous 
addition of TGFβ.
Directly depleting Runx1 in MCF10A cells 
results in loss of epithelial morphology and 
activation of EMT
We have shown by multiple lines of evidence that 
down-regulation of Runx1 is a key step during breast 
cancer EMT. However, we still could not distinguish 
whether decreased Runx1 expression drives the activation 
of EMT or is an outcome of EMT. To address that question 
and understand whether Runx1 can function directly to 
maintain normal epithelial morphology, we inhibited 
endogenous Runx1 expression in MCF10A cells using 
lentivirus that contained short-hairpin RNA targeting 
Runx1 (shRunx1) (Figure 6). We generated two different 
MCF10A shRunx1 cell lines using two different shRNA 
sequences (shR1-1, shR1-2). Compared to the parental 
and control (non-silencing) cells, we observed that 
Runx1-depleted MCF10A cells showed an obvious shift in 
morphology from cobblestone-like cells to more spindle-
shaped cells (Figure 6A). Western blot and Q-PCR analysis 
demonstrated endogenous Runx1 was down regulated at 
both the protein and mRNA levels (Figure 6B and 6C). 
Because the shRunx1 cells exhibited a morphological 
change consistent with loss of the epithelial phenotype, 
E-cadherin expression was examined. Runx1 knockdown 
cells showed a significant decrease of E-cadherin, as well 
as up-regulation of the mesenchymal genes Vimentin and 
N-cadherin (Figure 6C).
Taken together, these results indicate that depletion 
of Runx1 directly initiates EMT in MCF10A cells, and 
establishes for the first time that Runx1 is required to 
maintain the normal mammary epithelial phenotype. The 
mechanism for these biological activities involves Runx1 
binding to EMT-related target genes.
Previously it has been shown that both E-cadherin 
[23] and genes in TGFB family [24] have Runx1 binding 
sites. Thus to further support a direct role for Runx1 
regulation of E-cadherin and TGFβ signaling in MCF10A 
cells, a Runx1 ChIP-qPCR was performed (Figure 6D). 
Significant enrichment of Runx1 binding on E-cadherin 
(CDH1), TGFB2 and TGFBR3 genes were observed. The 
positions of the amplicons on tested genes are shown in 
Supplementary Figure 2. These results indicate that Runx1 
may directly bind to the E-cadherin gene and regulate its 
expression. Our findings also provide an additional line 
of evidence for a key function of Runx1 in blocking 
TGFβ signaling and maintaining epithelial morphology. 
Further the binding of Runx1 to the E-cadherin gene is 
also associated with the H3K4ac activating histone mark 
[25]. We searched for putative Runx1 binding sites and 
found 5 consensus motif sequences which are coincident 
with H3K4ac peaks present in MCF10A cells, but not in 
metastatic MDA-MB-231 cells (Supplementary Figure 3).
Depleting Runx1 in MCF7 breast cancer cells 
promotes EMT
The loss of epithelial morphology in normal-like 
mammary cells by knockdown of Runx1 (Figure 6) raises a 
compelling question regarding the role of Runx1 in breast 
cancer cells.Therefore, we tested whether this regulation 
also occurs in epithelial-like MCF7 breast cancer cells. 
Two shRunx1 (shR1-1, shR1-2) stable knockdowns in the 
MCF7 cell line were generated. Endogenous Runx1 was 
down regulated at both the protein and mRNA levels for 
both short-hairpin RNAs (Figure 7A and 7B). In these 
Runx1-depleted MCF7 cells, western blot and RT-Q-PCR 
analyses revealed a significant decrease of E-cadherin 
expression at both the protein and mRNA levels and 
up-regulation of the mesenchymal genes Vimentin and 
N-cadherin at the mRNA level (Figure 7C). Based on 
these results, we conclude that Runx1 is preventing EMT 
in both normal mammary cells (MCF10A) and breast 
cancer cells (MCF7), consistent with its function in 
maintaining an epithelial phenotype.
Overexpressing Runx1 in mesenchymal like 
breast cancer cells drives mesenchymal to 
epithelial transition (MET)
To further establish a definitive role for Runx1 
function in preserving the epithelial phenotype, we carried 
out a “rescue” study to examine the consequences of 
restoring Runx1 expression in mesenchymal like breast 
cancer cells (Figure 7D and 7E). Runx1 was ectopically 
expressed in tumorigenic MCF10AT1 cells, which 
resulted in increased E-cadherin expression and decreased 
Vimentin expression (Figure 7D and 7E). Notably, the 
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Figure 6: Depleting Runx1 in MCF10A cells promotes a mesenchymal-like phenotype. A. MCF10A cells treated with 
shRunx1 show morphological changes toward an EMT- like state. B. Western blot analyses of lysates from MCF10A cells treated with 
shRunx1 show decreased protein expression of Runx1 and E-cadherin. C. RT-qPCR analyses of RNA from MCF10A cells treated with 
shRunx1 show decreased gene expression of E-cadherin and activation of mesenchymal marks of N-cadherin and Vimentin. Student’s t test 
* p value <0.05, ** p value <0.01 for MCF10A shRunx1 cells compared to the MCF10A ns cells. Error bars represent the standard error of 
the mean (SEM) from three independent experiments. D. ChIP-qPCR confirmation of Runx1 occupancy at CDH1, TGFB2 and TGFBR1. 
ZNF188 (NC1) and ZNF333 (NC2) were used as the negative control as Runx1 are predicted not to bind these genes. Data obtained with 
antibodies against Runx1 are normalized to input control.
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E-cadherin level is only increased at mRNA level but not 
protein level under transient transfection conditions (data 
not shown). This key finding shows that overexpression of 
Runx1 in mesenchymal cancer cells drives the cells back 
to the epithelial stage. These observations provide direct 
evidence that Runx1 prevents EMT.
Runx1 expression in breast tumors correlates 
with metastasis, tumor subtype and survival
We next evaluated Runx1 expression in breast 
cancer patient tissues. With a highly specific Runx1 
antibody, we applied immunohistochemistry to determine 
Figure 7: Runx1 controls EMT-MET in non-metastatic breast cancer cells. Two breast cancer cell lines MCF7 (epithelial-like) 
A-C. and MCF10AT1 (mesenchymal-like) D, E. were examined for Runx1 knockdown or ectopic expression, respectively. (A) Western 
blot analyses of lysates from MCF7 cells with Runx1 depletion show decreased protein expression of Runx1 and E-cadherin. (B) RT-
qPCR of RNA from MCF7 cells treated with shRunx1 shows decreased gene expression of Runx1. (C) RT-qPCR shows decreased gene 
expression of E-cadherin and increased gene expression of N-cadherin and Vimentin in Runx1 depleted MCF7 cells. Student’s t test * p 
value <0.05, ** p value <0.01 for MCF7 shRunx1 cells compared to the MCF7ns cells. Error bars represent the standard error of the mean 
(SEM) from three independent experiments. (D) RT-qPCR of RNA from MCF10AT1 cells overexpressing Runx1 show increased gene 
expression of E-cadherin and decreased gene expression of Vimentin. Student’s t test * p value <0.05 for MCF10AT1 Runx1 overexpression 
cells compared to the MCF10AT1 EV cells. Error bars represent the standard error of the mean (SEM) from three independent experiments. 
(E) Western blot analyses of lysates from MCF10AT1 cells treated with Runx1 overexpression show increased protein expression of Runx1 
and decreased expression of Vimentin.
Oncotarget17620www.impactjournals.com/oncotarget
the expression pattern of Runx1 in different types of 
breast cancer using a Tissue Microarray (TMA) of 185 
tumors and 6 control normal adjacent tissue sections. 
The results identified that Runx1 expression is associated 
with breast cancer stages and subtypes. We observed 
Runx1 expression at high levels in all normal and benign 
mammary epithelial tissues (Figure 8A). Runx1 is also 
expressed in breast cancer samples including ductal 
carcinoma in situ and invasive ductal carcinoma (Figure 
8A). However, breast cancer cells metastatic to the 
lymph node showed significantly less Runx1 expression 
compared with the primary tumor site (Figure 8A and 
8B). Quantification of Runx1 levels at primary sites and 
lymph metastatic sites in 50 patients showed that Runx1 
is significantly lower (p=0.005 using two tailed t test) in 
lymph samples (Figure 8C). We also observed slightly 
higher Runx1 levels in grade 1 compared with grade 2 
tumors (Supplementary Figure 4).
We further investigated the relationship of Runx1 
expression to clinical outcomes through mining of The 
Cancer Genome Atlas (TCGA) database. Runx1 was found 
to be under-expressed in several breast cancer subtypes, 
including Luminal B, Her2 enriched and basal like 
breast cancers, which all have a poor prognosis (Figure 
8D). Luminal A subtype, which is generally associated 
with a good prognosis, showed Runx1 levels equivalent 
to normal-like breast tissue. However 5% of samples in 
this subtype have Runx1 somatic mutations [10], with 
the majority located in the Runx1 DNA-binding domain, 
which can compromise Runx1 transcriptional activity. 
We conclude from these data that Runx1 expression is 
subtype-dependent and correlates with prognosis.
Runx1 expression levels were also compared with 
patient survival rates using a data set (GSE3494-U133A) 
in the Gene Expression Omnibus database (Figure 8E). 
Our analyses shows that patients with low Runx1 levels in 
their tumors exhibit poor survival relative to patients with 
high Runx1 expression.
Taken together our data demonstrate that Runx1 
functions as a tumor suppressor in normal epithelial cells, 
by sustaining the epithelial phenotype and preserving 
the epithelial integrity. Loss of Runx1 is not only 
accompanied with EMT (Figures 2-5) but can also initiate 
the transformation process (Figures 6 and 7). Therefore, 
loss of Runx1 normal activities in tumor tissues may serve 
as an indicator of poor prognosis for breast cancer patients 
as revealed in several clinical studies (Figure 8). We 
conclude from these clinical data that as tumors advance 
from early stage to a more aggressive phenotype, loss of 
Runx1 may promote tumor progression.
DISCUSSION
Our study has established a crucial role for Runx1 
in maintaining the normal epithelial phenotype. This 
finding is supported by our demonstration that Runx1 is 
decreased during EMT and that loss of endogenous Runx1 
initiates and promotes EMT which is also accompanied by 
changes in the morphology of mammary epithelial cells. 
Using two independent methods to induce EMT, either 
by adding TGFβ or removing required growth factors 
which increases/activates TGFβ expression, we observed 
significantly decreased Runx1 expression. Further, 
Runx1 re-expression rescues the epithelial phenotype 
following TGFβ treatment, which assures maintenance 
of normal epithelial cell morphology and prevents 
EMT. By inhibition of Runx1 in MCF10A (normal) 
and MCF7 (epithelial like breast cancer) cells, together 
with re-expression in MCF10AT1 (malignant cells with 
low Runx1 levels), we provide direct evidence that loss 
of Runx1 directly contributes to the initiation of EMT 
in breast cancer, while the presence of Runx1 restores 
the epithelial phenotype. Together these findings have 
revealed, for the first time, that the expression of Runx1 
has a critical function in preserving epithelial morphology 
in mammary epithelial cells and preventing EMT; thus, 
Runx1 can be considered as a tumor suppressor in normal 
epithelial cells.
Here we focused our study on normal mammary 
epithelial and epithelial like breast cancer cells, and 
discovered a key function for Runx1 in preventing EMT. 
We examined the mechanisms by which Runx1 regulates 
EMT in cancer progression. First, we show Runx1 is a 
positive regulator of the epithelial marker E-cadherin. 
Upon loss of Runx1, the expression level of E-cadherin is 
strikingly decreased. We also showed that Runx1 directly 
binds to a consensus motif in the E-cadherin gene using 
ChIP-qPCR. Second, we demonstrate Runx1 operates 
downstream of the TGFβ pathway and functions as a 
suppressor of TGFβ regulation. Runx1 is well established 
to mediate TGFβ-BMP signaling by forming co-regulatory 
complexes with SMADs [19, 26]. Our RNA-Seq analysis 
of growth factor-depleted cells suggests that loss of 
Runx1 is coupled with activation of the TGFβ pathway. 
This was confirmed experimentally by showing that 
Runx1 is decreased upon TGFβ treatment and Runx1 
rescues TGFβ induced EMT. Supporting these molecular 
mechanisms, Runx1 has known properties that establish 
cell phenotypes, including the hematopoietic lineage 
[27], regulating quiescent hair follicle bulge stem cells to 
differentiate to early progenitor hair germ cells [28]. Very 
recently Runx1 was shown to be transiently upregulated 
early in hESC differentiation to mesendodermal lineages 
via Runx1-TGFB2 signaling and that loss of Runx1 
impaired epithelial differentiation [29]. Thus our studies, 
which have now identified a cellular function for Runx1 
in normal mammary cells, are consistent with these 
other normal tissues to support their cell type specific 
phenotype. We have further studied the consequence of 
disturbing normal Runx1 function in breast cancer cells 
and provided evidence that Runx1 loss of function has a 
significant effect on cancer-related mechanisms.
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Figure 8: Runx1 expression in breast tumors correlates with metastasis, tumor subtype and survival. A. Representative 
tissue microarray images of Runx1 in normal adjacent tissue (NAT), fibroadenoma, invasive ductal carcinoma, and tumor metastasis to 
lymph. B. Representative of TMAs (n=50) showing two patients’ primary tumor and their lymph metastasis with Runx1 positive cells 
(brown stain). Two tailed t test ** p<0.005 between primary tumor and lymph metastatic sites. C. Distribution of Runx1 staining scores 
for 50 patients with primary breast tumor and lymph metastasis. Using a semi-quantitative scoring system, three researchers blindly scored 
TMAs. D. Runx1 mRNA is decreased in breast cancer subtypes. E. Kaplan-Meier analysis showed higher overall survival in patients with 
higher Runx1 mRNA expression (GSE3494-U133A). Gehan-Breslow-Wilcoxon test with p value<0.0001 compared with high Runx1 
expression patients and low Runx1 expression patients.
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Repression, overexpression, and/or deregulated 
functioning of Runx1 have been shown to cause cancers 
[30]. TGFβ is a well-known EMT inducer and has a dual 
role in breast cancer progression [31]. In normal epithelial 
cells and early stage breast cancer, TGFβ acts as a tumor 
suppressor, yet at later stages of tumor progression can 
promote cancer cell migration, invasion and metastasis 
[32]. Our results have provided evidence that TGFβ 
is an upstream regulator of Runx1. Because Runx1 is 
downstream of TGFβ, Runx1 may also have different 
functions depending on the specific cellular context [33]. 
For example, while Runx1 has been shown to function as 
a tumor suppressor in prostate cancer [34], it acts as an 
oncogene in ovarian cancer [35] and in a mouse model of 
breast cancer [33]. Our identification of TGFβ as a Runx1 
upstream regulator provides insight into the compromised 
mechanisms of Runx1 function that are associated with 
breast cancer.
Runx1 is also subject to the hormonal status of 
cells. Treating ER+ breast cancer cells with 17β-estradiol 
promotes EMT [36] and also decreases Runx1 expression 
[37]. In turn, depletion of Runx1 represses the expression 
of estrogen receptor α [38], suggesting a negative 
feedback loop in progression of ER+ breast cancer. 
Our data show MCF7 ER+ breast cancer cells can be 
induced into EMT by Runx1 depletion. One study using 
computational analysis revealed that Runx1 is highly 
correlated with mammary stem cell differentiation 
[39]. Other studies showed that Runx1 is important for 
mammary gland maturation, and its interaction with ERα 
is necessary for luminal development and may prevent 
breast cancer progression [38, 39]. It also has been shown 
that Runx1 represses WNT pathways, which allows ER 
to be expressed in luminal breast cancer cells [22]. All 
these pieces of evidence raise the hypothesis that Runx1 
could function as a tumor suppressor in ER positive breast 
cancer; here we clearly demonstrate Runx1 has a direct 
role to prevent EMT in MCF7 ER+ breast cancer cells, 
and thus establishes Runx1 as a tumor suppressor.
In addition to Runx1-mediated mechanisms 
downstream of TGFβ (feedback loop) and upstream 
hormonal regulation of Runx1, miRNAs are also a likely 
mechanism contributing to the down regulation of Runx1 
during EMT. MicroRNAs are known to promote/inhibit 
EMT (e.g., miR-200 family, miR-27 and miR-30) [40]. 
Our analysis using TargetScan7.0 indicates that most of 
these miRNAs also target the Runx1 3’UTR. It has been 
shown that miR27a [41], miR144 [37] and miR387 [42], 
which are upregulated during breast cancer progression, 
are directly down-regulating Runx1. The convergence of 
these multiple pathways that inhibit Runx1 expression 
leads us to conclude that loss of Runx1 is an important 
mechanistic step in breast cancer initiation and/or 
progression.
Examination of TCGA and other public datasets 
identified loss of Runx1 correlates with poor prognosis 
(Figure 8C) and poor survival (Figure 8D). It has been 
shown in breast tumors that the majority of EMT markers 
are expressed in basal layer cells [43]. Also reported is that 
basal subtypes of breast cancer are more aggressive and 
metastatic compared to the luminal subtypes [44]. TCGA 
data show that Runx1 is expressed at the lowest level in 
patients with basal like breast cancer. These findings are 
consistent with our identification of a Runx1 function in 
preserving the epithelial phenotype in normal like basal 
cells (MCF10A). Loss of Runx1 expression may cause the 
basal cells to lose their epithelial morphology, phenotype 
integrity and become more susceptible to initiation of 
EMT. Therefore, our functional studies focused on the 
role of Runx1 in basal-like mammary epithelial cells 
(MCF10A).
Intact Runx1 function is also important for Luminal 
A breast cancer. Genetic studies show Runx1 is mutated in 
5% of Luminal A subtype breast cancer patients [10, 11]. 
A recent study suggested that in MCF7 cells, disruption 
of Runx1 function might contribute to development 
of ER+ luminal breast cancer in the context of either 
TP53 or RB1 loss [38]. Significantly, we demonstrated 
that loss of Runx1 in luminal like breast cancer cells 
(MCF7) can promote EMT (Figure 7). Taken together, 
these biochemical and clinical data support the emerging 
concept that Runx1 is a tumor suppressor and that loss of 
Runx1 is associated with the progression of breast cancer.
Our studies demonstrate a clear reduction of 
endogenous Runx1 in two cell models (MCF7 and 
MCF10AT1) of breast cancer. This finding is consistent 
with human TMA data that show the strongest Runx1 
staining (66% strong or moderate levels) in normal cases, 
compared with 29% and 35% in DCIS and IDC samples, 
respectively [43, 44]. However, this human data is in 
contrast to findings in the MMTV-PyMT mouse model 
of breast cancer [33], where Browne et al. reported that 
Runx1 steadily increased during tumor growth. Thus, the 
decreased Runx1 in human samples with increased disease 
progression indicates Runx1 has distinct functional 
activities that differ between mouse and human breast 
tumors.
In conclusion, we identified Runx1 as a key 
transcription factor in basal epithelial breast cells through 
its ability to maintain normal epithelial morphology. Our 
studies offer Runx1 as a novel bio-therapeutic molecule 
for breast cancer intervention.
MATERIALS AND METHODS
Cell lines and cultures
Human breast cancer cell lines MCF10A, MCF7, 
MDA-MB-231 and T47D cells were purchased from 
ATCC. MCF10AT1 and MCF10CA1a cells are a gift from 
Jeff Nickerson’s lab.
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MCF10A cells were grown in DMEM: F12 
(Hyclone: SH30271, Thermo Fisher Scientific, Waltham, 
MA, USA) with 5% (v/v) horse serum (Gibco: 16050, 
Thermo Fisher Scientific, Waltham, MA, USA) + 10 
μg/ml human insulin (Sigma Aldrich, St. Louis, MO: 
I-1882) + 20 ng/ml recombinant hEGF (Peprotech, Rocky 
Hill, NJ, USA: AF-100-15) + 100 ng/ml cholera toxin 
(Sigma Aldrich: C-8052) + 0.5 μg/ml hydrocortisone 
(Sigma Aldrich: H-0888) 50 IU/ml penicillin/50 μg/ml 
streptomycin and 2 mM glutamine (Life Technologies, 
Carlsbad, CA, USA: 15140-122 and 25030-081, 
respectively). TGFβ induced EMT in MCF10A cells was 
initiated by addition of 10 ng/ml TGFβ1 (R&D Systems, 
Minneapolis, MN, USA) to the medium. Growth factors 
starvation induced EMT in MCF10A cells was performed 
as previously described [16]. Briefly, MCF10A cells were 
plated in completed medial and at day 2, the medium was 
switched to DMEM: F12, with 5% (v/v) horse serum and 
50 IU/ml penicillin/50 μg/ml streptomycin without added 
growth factors. The cells were maintained in this medium 
for up to 14 days until the morphological change was 
observed.
MCF10AT1 cells were grown in the same medium 
as MCF10A cells. MCF10CA1a cells were grown in 
DMEM: F with 12, 5% (v/v) horse serum with 50 IU/ml 
penicillin/50 μg/ml streptomycin and 2 mM glutamine. 
MCF7 cells were maintained in Dulbecco modified 
Eagle medium (DMEM) high glucose (Fisher Scientific: 
Thermo Fisher Scientific, Waltham, MA, USA: MT-10-
017-CM) supplemented with 10% (v/v) FBS (Atlanta 
Biologicals, Flowery Branch, GA, USA: S11550), 50 
IU/ml penicillin/50 μg/ml streptomycin. T47D cells 
were maintained in RPMI 1640 with phenol red (Fisher 
Scientific: MT-10-040-CM) supplemented with 10% 
(v/v) FBS and 50 IU/ml penicillin/50 μg/ml streptomycin. 
MDA-MB-231 cells were cultured in alpha minimal 
essential medium (α-MEM) (Life Technologies: A10490-
01) containing 10% (v/v) FBS and 50 IU/ml penicillin/50 
μg/ml streptomycin. MCF10CA1a cells were transfected 
using FuGENE-6 (Roche, Indianapolis, IN, USA) 
according to the instructions of the manufacturer.
Lentiviral plasmid preparation and viral vector 
production
Lentivirus-based RNAi transfer plasmids 
with pGIPZ shRunx1 (clone V2LHS_150257 and 
V3LHS_367631, GE Dharmacon) and pGIPZ non-
silencing (Cat No. RHS4346, GE Dharmacon) were 
purchased from Thermo Scientific. To generate lentivirus 
vectors, 293T cells in 10 cm culture dishes were co-
transfected with 10 μg of pGIPZ shRunx1 or pGIPZ non-
silencing, with 5 μg of psPAX2, and 5 μg of pMD2.G 
using lipofectamine 2000 reagent (Life Technologies). 
Viruses were harvested every 48 h post-transfection. After 
filtration through a 0.45 μm-pore-size filter, viruses were 
concentrated by using LentiX concentrator (Clontech, 
Mountain View, CA, USA).
Gene delivery by transfection and infection
For shRNA-mediated knockdown of Runx1 
expression, MCF10A or MCF7 cells were plated in six-
well plates (1x105 cells per well) and infected 24 h later 
with lentivirus expressing shRunx1 or nonspecific shRNA. 
Briefly, cells were treated with 0.5 ml of lentivirus and 
1.5 ml complete fresh DMEM-F12 per well with a 
final concentration of 4 μg/ml polybrene. Plates were 
centrifuged upon addition of the virus at 1460 × g at 
37°C for 30 min. Infection efficiency was monitored by 
GFP co-expression at 2 days post infection. Cells were 
selected with 2 μg/ml puromycin (Sigma Aldrich P7255-
100MG) for at least two additional days. After removal of 
the floating cells, the remaining attached cells were passed 
and analyzed.
Western blotting
Cells were lysed in RIPA buffer and 2X SDS 
sample buffer supplemented with cOmplete, EDTA-free 
protease inhibitors (Roche Diagnostics) and MG132 
(EMD Millipore San Diego, CA, USA). Lysates were 
fractionated in an 8.5% acrylamide gel and subjected 
to immunoblotting. The gels are transferred to PVDF 
membranes (EMD Millipore) using a wet transfer 
apparatus (Bio-Rad Laboratories, Hercules, CA, USA). 
Membranes were blocked using 5% Blotting Grade 
Blocker Non-Fat Dry Milk (Bio-Rad Laboratories) and 
incubated overnight at 4°C with the following primary 
antibodies: a rabbit polyclonal Runx1 (Cell Signaling 
Technology, Danvers, MA, USA:#4334, 1:1000); a mouse 
monoclonal to E-cadherin (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA: sc21791, 1:1000); a mouse 
monoclonal Vimentin (Santa-Cruz Biotechnology sc-
6260, 1:1000); a mouse monoclonal to β-Actin (Cell 
Signaling Technology #3700, 1:1000); a rabbit polyclonal 
LaminB1 (Abcam, Cambridge, UK: 16048, 1:2000); a 
rabbit polyclonal N-cadherin (Santa Cruz Biotechnology 
sc-7939, 1:2000). Secondary antibodies conjugated 
to HRP (Santa Cruz Biotechnology) were used for 
immunodetection, along with the Clarity Western ECL 
Substrate (Bio-Rad Laboratories) on a Chemidoc XRS+ 
imaging system (Bio-Rad Laboratories).
Immunofluorescence staining microscopy
Cells grown on coverslips were fixed with using 
3.7% formaldehyde in phosphate buffered saline (PBS) 
for 10 min. Cells were then permeabilized in 0.1% 
Triton X-100 in PBS, and washed in 0.5% Bovine Serum 
Albumin in PBS. Detection was performed using a rabbit 
polyclonal Runx1 antibody (Cell Signaling Technology 
#4336), a mouse monoclonal Vimentin (Santa Cruz 
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Biotechnology sc-6260), a rabbit polyclonal N-cadherin 
(Santa Cruz Biotechnology sc-7939) and a mouse 
monoclonal to E-cadherin (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA). Staining was performed using 
fluorescent secondary antibodies; for rabbit polyclonal 
antibodies a goat anti-rabbit IgG (H+L) secondary 
antibody, Alexa Fluor® 488 conjugate (Life Technologies 
A-11008), was used and for mouse monoclonal a F(ab')2-
goat anti-mouse IgG (H+L) secondary antibody, Alexa 
Fluor® 488 conjugate was used (Life Technologies 
A-11001).
Quantitative PCR
RNA was isolated with Trizol (Life Technologies) 
and cleaned by DNase digestion (Zymo Research, 
Irvine, CA, USA). RNA was reversed transcribed using 
SuperScript II and random hexamers (Life Technologies). 
cDNA was then subjected to quantitative PCR using 
SYBR Green technology (Applied Biosystems, Foster 
City, CA, USA). Sequences of primers used in the paper. 
Runx1 Forward: AACCCTCAGCCTCAGAGTCA, Runx1 
Reverse: CAATGGATCCCAGGTATTGG; E-cadherin 
Forward: GGAAGTCAGTTCAGAGCATC, E-cadherin 
Reverse: AGGCCTTTTGACTGTAATCACACC; 
N-cadherin Forward: 
TGTTTGACTATGAAGGCAGTGG, N-cadherin Reverse: 
TCAGTCATCACCTCCACCAT; Vimentin Forward: 
AGGAAATGGCTCGTCACCTTCGTGAATA, Vimentin 
Reverse: GGAGTGTCGGTTGTTAAGAACTAGAGCT; 
GAPDH Forward: TGTGGTCATGAGTCCTTCCA, 
GAPDH Reverse: ATGTTCGTCATGGGTGTGAA; 
HPRT Forward: TGCTGACCTGCTGGATTACA, HPRT 
Reverse: TCCCCTGTTGACTGGTCATT; β-Actin 
Forward: AGCACAGAGCCTCGCCTTT, β-Actin 
Reverse: CGGCGATATCATCATCCAT.
Tissue microarray
Formalin-fixed paraffin-embedded (FFPE) human 
breast cancer samples were obtained from the UMMS 
tissue bank and FFPE human breast cancer tissue 
microarrays (TMA) from US BioMax (Rockville, MD, 
USA). TMAs (BR1503a & BR10010) were obtained 
from US BioMax. Sample information pertaining to 
Type, Grade, Stage, TNM, were provided by US BioMax. 
BR1503a is a primary breast tissue array of 150 samples 
of 75 patient cases: three cases of adjacent normal breast 
tissue, three cases of breast fibroadenoma, two cases of 
breast cystosarcoma phyllodes, seven cases of breast 
intraductal carcinoma, and 60 cases of breast invasive 
ductal carcinoma. Duplicate cores per case. BR10010 is a 
breast carcinoma and matched metastatic carcinoma array 
of 100 samples of 50 patient cases: 46 cases of invasive 
ductal carcinoma, one case of micropapillary carcinoma, 
two cases of invasive lobular carcinoma, and one case 
of neuroendocrine carcinoma. Duplicate cores per case. 
RUNX1 staining was done as previously described 
[45] using RUNX1 Rabbit Polyclonal 4334 from Cell 
Signaling Technology. Each tissue section was imaged and 
independent researchers blindly scored the sections based 
on the metric in Figure 8.
Analysis of Runx1 expression in various cancers 
using public data sets
Runx1 expression was analyzed in various breast 
cancer subtype types using the TCGA database (www.
cbioportal.org) [10]. The PROGgene database (www.
compbio.iupui.edu/proggene) was used to identify the data 
sets for survival analysis and re-analyzed the public GEO 
data sets (www.ncbi.nlm.nih.gov/gds) (GSE3494-U133A).
RNA-Seq, ontology, and pathway analysis
RNA was isolated using DirectZol RNA mini prep 
kit (Zymo Research), quantified by Qubit HS RNA assay 
(Thermo Fisher Scientific) and assayed for RNA integrity 
by Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). Total RNA was depleted of ribosomal RNA, reverse 
transcribed and strand-specific adapters added following 
manufacturer’s protocol (TruSeq Stranded Total RNA 
Library Prep kit with Ribo-Zero Gold, Illumina, San Diego, 
CA, USA) with the exception that the final cDNA libraries 
were amplified using the Real-time Library Amplification 
Kit (Kapa Biosystems, Wilmington, MA, USA) to prevent 
over-amplification of libraries. Generated cDNA libraries 
were assayed for quality then sequenced as single-end 100 
bp reads (IlluminaHiSeq1000, UVM Advanced Genome 
Technologies Core). Sequence files (fastq) were mapped 
to the most recent assemblies of the human genome (hg38) 
using TopHat2 [46]. Expression counts were determined by 
HTSeq [47] with recent gene annotations (Gencode v22) 
[48]. Differential expression was analyzed by DESeq2 
[49]. Correlation between replicates and differential gene 
expression between time points was assessed by principal 
component analysis (PCA). RNA-Seq data have been 
deposited in the GEO under accession codes GSE85857. 
In addition, mRNA expression data was uploaded to 
IPA (www.ingenuity.com) and analyzed using default 
parameters. The expression heat map was generated using 
GENE-E (Broad Institute, MA, USA www.broadinstitute.
org/cancer/software/GENE-E/). Fifty-eight EMT genes 
were selected by using the list from [50, 51].
ChIP-qPCR
Runx1 ChIP-qPCR was performed essentially as 
described [52]. Briefly, 200,000 MCF10A cells were 
cross-linked, lysed and sonicated to obtain DNA fragments 
mostly in the 200-1000-bp range. Immunoprecipitation 
was performed at 4°C overnight with anti-Runx1 antibody 
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(4334, Cell Signaling Technology) at a 1:15 antibody to 
chromatin ratio. Primers used in ChIP-qPCR are listed 
below: CDH1 Forward: CCCAACCTGACCACAGGAAT, 
CDH1 Reverse: GCTGCATGCGTAACAACACA; 
TGFB2 Forward: AGTCCTCCTCCCCCTAATGT, 
TGFB2 Reverse: CAGGGTATAGGCCACGACTG; 
TGFBR3 Forward: TCTTTGTAGCCTGCTGGGTT, 
TGFBR3 Reverse: CCCCCATCCTTACAAGTGGTT; 
ZNF333 (negative control 1) Forward: 
TGAAGACACATCTGCGAACC, ZNF333 Reverse: 
TCGCGCACTCATACAGTTTC; ZNF180 (negative 
control 2) Forward: TGATGCACAATAAGTCGAGCA, 
ZNF180 Reverse: TGCAGTCAATGTGGGAAGTC.
Statistical analysis
The results were reported as Mean ± S.E.M. unless 
otherwise indicated, and Student’s t-Tests were used to 
calculate statistical significance.
The following datasets were generated:
RNA-sequences: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE85857, publicly available at NCBI 
Gene Expression Omnibus (accession no. GSE 85857).
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